Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 637-653 , December 2006

The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective

  • Frédéric Baron, MD (Research assistant, National Fund for Scientific Research, Belgium)
  • Rainer Storb, MD (Head, Transplantation Biology Program, FHCRC Professor of Medicine, UW)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 667 4407; Fax: +1 206 667 6124.

References 

  1. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde. 1909;5:273–290
  2. Schwartz RS. Another look at immunologic surveillance (Review). The New England Journal of Medicine. 1975;293(4):181–184
  3. Burnet M. The Clonal Selection Theory of Acquired Immunity. London: Cambridge University Press; 1959;
  4. Burnet FM. The concept of immunological surveillance (Review). Progress in Experimental Tumor Research. 1970;13:1–27
  5. Thomas L. On immunosurveillance in human cancer. Yale Journal of Biology & Medicine. 1982;55(3–4):329–333
  6. Wilson DB. Immunological surveillance. Science. 1970;169(949):1006–1011
  7. Stutman O. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. Journal of the National Cancer Institute. 1979;62(2):353–358
  8. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape (Review). Nature Immunology. 2002;3(11):991–998
  9. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting (Review). Immunity. 2004;21(2):137–148
  10. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(13):7556–7561
  11. Smyth MJ, Thia KY, Street SE, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. The Journal of Experimental Medicine. 2000;192(5):755–760
  12. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111
  13. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. International Journal of Cancer. 1995;60(2):183–189
  14. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. Journal of the National Cancer Institute. 2005;97(6):407–409
  15. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. The New England Journal of Medicine. 1957;257:491–496
  16. Little M-T, Storb R. History of haematopoietic stem-cell transplantation. Nature Reviews Cancer. 2002;2:231–238
  17. Mathe G, Amiel JL, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Research. 1965;25(9):1525–1531
  18. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine. 1979;300:1068–1073
  19. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine. 1981;304:1529–1533
  20. Morris E, Hart D, Gao L, et al. Generation of tumor-specific T-cell therapies. Blood Reviews. 2006;20:61–69
  21. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines (Review). Journal of Clinical Oncology. 2005;23(26):6421–6428
  22. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–3561
  23. Sievers EL, Larson RA, Stadmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology. 2001;19(13):3244–3254
  24. Caligiuri MA, Velardi A, Scheinberg DA, et al. Immunotherapeutic approaches for hematologic malignancies (Review). Hematology. 2004;337–353
  25. Pagel JM, Matthews DC, Appelbaum FR, et al. The use of radioimmunoconjugates in stem cell transplantation (Mini-review). Bone Marrow Transplantation. 2002;29:807–816
  26. Pagel JM, Appelbaum FR, Gooley T, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184–2191
  27. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology. 2004;32(1):28–35
  28. Barnes DWH, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow: II. British Journal of Haematology. 1957;3:241–252
  29. Bortin MM, Rimm AA, Rose WC, et al. Graft-versus-leukemia. V. Absence of antileukemic effect using allogeneic H-2-identical immunocompetent cells. Transplantation. 1974;18:280–283
  30. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  31. Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985;66:664–672
  32. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175–178
  33. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine. 1989;320:828–834
  34. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1728
  35. Kolb HJ, Mittermüller J, Clemm Ch, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  36. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86(5):2041–2050
  37. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology. 1997;15(2):433–444
  38. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology. 2000;18(16):3031–3037
  39. Peggs KS, Mackinnon S, Linch DC. The role of allogeneic transplantation in non-Hodgkin's lymphoma. British Journal of Haematology. 2005;128(2):153–168
  40. Kolb HJ, Schmidt C, Barrett AJ, et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767–776
  41. Storb R. Allogeneic hematopoietic stem cell transplantation – yesterday, today, and tomorrow. Experimental Hematology. 2003;31:1–10
  42. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Seminars in Immunopathology. 2004;26:71–94
  43. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Molecular Therapy. 2006;13(1):26–41
  44. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–4536
  45. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–763
  46. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400
  47. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. The New England Journal of Medicine. 2000;343(11):750–758
  48. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104(13):3865–3871
  49. Mohty M, de Lavallade H, Ladaique P, et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia. 2005;19(6):916–920
  50. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Journal of Clinical Oncology. 2005;23(9):1993–2003
  51. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89(8):3048–3054
  52. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620–1629
  53. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021–2030
  54. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biology of Blood and Marrow Transplantation. 2002;8:512–520
  55. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 2001;98(13):3584–3588
  56. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103(1):78–84
  57. Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003;102(8):2777–2785
  58. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood. 2004;104(4):961–968
  59. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood. 2004;104(5):1550–1558
  60. Parikh CR, Schrier RW, Storer B, et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases. 2005;45(3):502–509
  61. Chien JW, Maris MB, Sandmaier BM, et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11:288–296
  62. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004;104(8):2254–2262
  63. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia. 2005;19:822–828
  64. Sandmaier BM, Maris M, Maloney DG, et al. Low-dose total body irradiation (TBI) conditioning for hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies: a five-year experience. [Abstract] Blood. 2003;102:(Part 1):(11)78a–9a, #264
  65. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102(2):756–762
  66. Feinstein LC, Sandmaier BM, Hegenbart U, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology. 2003;120(2):281–288
  67. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9):3447–3454
  68. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104(12):3535–3542
  69. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. Journal of Clinical Oncology. 2005;23(16):3819–3829
  70. Kerbauy FR, Storb R, Hegenbart U, et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia. 2005;19:990–997
  71. Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation. 2005;11:272–279
  72. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135
  73. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia (AML) by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation (HCT) from related and unrelated donors. Journal of Clinical Oncology. 2006;24:444–453
  74. Herberman RB, Djeu J, Kay HD, et al. Natural killer cells: characteristics and regulation of activity. Immunological Reviews. 1979;44:43–70
  75. Livnat S, Seigneuret M, Storb R, et al. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation. Journal of Immunology. 1980;124:481–490
  76. Raff RF, Loughran TP, Deeg HJ, et al. Role of radiation-resistant large granular lymphocytes in the rejection of unrelated DLA-nonidentical marrow grafts in dogs. Transplantation Proceedings. 1987;19:2718–2720
  77. Raff RF, Sandmaier BM, Graham T, et al. ‘Resistance’ to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Experimental Hematology. 1994;22:893–897
  78. Fischer A, Le Deist F, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy (Review). Immunological Reviews. 2005;203:98–109
  79. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells (Review). Annual Review of Immunology. 1996;14:619–648
  80. Moretta L, Bottino C, Pende D, et al. Different checkpoints in human NK-cell activation (Review). Trends in Immunology. 2004;25(12):670–676
  81. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–738
  82. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100
  83. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814–819
  84. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825–3827
  85. Bornhauser M, Schwerdtfeger R, Martin H, et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood. 2004;103(7):2860–2861
  86. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105(6):2594–2600
  87. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants (Review). Nature Reviews Immunology. 2003;3(2):108–122
  88. Frohn C, Schlenke P, Kirchner H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology. 1997;92(4):567–570
  89. Shilling HG, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. Journal of Immunology. 2002;169(1):239–247
  90. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology. 2004;172(1):644–650
  91. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63(3):204–211
  92. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878–4884
  93. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine. 2000;6(9):1018–1023
  94. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nature Reviews Cancer. 2004;4(5):371–380
  95. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. The New England Journal of Medicine. 1995;333:1038–1044
  96. Heslop HE, Smith CA, Ng C, et al. Efficacy of adoptively transferred virus specific cytotoxic T lymphocytes for prophylaxis and treatment of EBV lymphoma. [Abstract] Blood. 1996;88:(supplement 1): 681a, #2713
  97. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy (Review). Molecular Therapy. 2004;10(1):5–18
  98. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine. 2004;10(9):909–915
  99. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood. 1997;89(9):3129–3135
  100. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. The New England Journal of Medicine. 1982;306(9):517–522
  101. Coscia M, Mariani S, Battaglio S, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;18(1):139–145
  102. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99(5):1517–1526
  103. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–497
  104. Linenberger ML, Maloney DG, Bernstein ID. Antibody-directed therapies for hematologic malignancies (Review). Trends in Molecular Medicine. 2002;8(2):69–76
  105. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–445
  106. Georges GE, Maris MB, Sandmaier BM, et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma. [Abstract] Blood. 2004;104:(Part 1):(11)754a, #2756
  107. Burroughs LM, Maris MB, Sandmaier BM, et al. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). [Abstract] Biology of Blood and Marrow Transplantation. 2004;10:(supplement 1):(2)73–4, #197

PII: S1521-6926(06)00039-9

doi: 10.1016/j.beha.2006.06.002

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 637-653 , December 2006

Article Tools

* Image Usage & Resolution